MedTrace Logo

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT05368285 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 208

Last updated 2025-03-26

No results posted yet for this study

Summary

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

Conditions

Interventions

BIOLOGICAL

barzolvolimab

Subcutaneous Administration

DRUG

Matching Placebo

Subcutaneous Administration

Sponsors & Collaborators

  • Celldex Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-19
Primary Completion
2023-09-28
Completion
2024-12-20
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Estonia
  • Georgia
  • Germany
  • Hungary
  • Poland
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05368285 on ClinicalTrials.gov